Truveta is a real-world intelligence company transforming medical science with unprecedented data and AI. Truveta powers breakthrough discoveries, accelerates regulatory-grade evidence, and unlocks ...
Certain low-risk or mature devices may see reduced trial requirements, but the broader trend is toward augmenting—not ...
Understand where real-world evidence most effectively complements or substitutes traditional trial data, from post-market surveillance and label expansion to challenging areas such as rare disease ...
PhaseV, a leader in AI/ML for clinical development, today announced the launch of its new Enrollment Lab solution at the 17th ...
Pragmatic clinical trials are designed to evaluate the effectiveness of interventions under the conditions of routine clinical practice, thereby addressing the gap between traditional randomised ...
Real-world evidence helps pharmaceutical companies and payers communicate more effectively. In this Q&A, Cate Lockhart, PharmD, PhD, chief science officer of the Academy of Managed Care Pharmacy (AMCP ...
Recently, the U.S. Food and Drug Administration (FDA) issued a guidance document entitled Use of Real-World Evidence to Support ...
Real-world evidence (RWE) empowers payers and providers to make more informed, cost-effective treatment. Read more here: ...
Angela Jia, MD, PhD, is a radiation oncologist specializing in stereotactic body radiation therapy (SBRT), adaptive radiotherapy, and clinical trials focused on prostate, bladder, and kidney cancers.
In the largest real-world study of its kind with 428,707 patients, the Zio LTCM service outperformed other studied monitoring approaches in cardiac arrhythmia diagnostic yield, time to diagnosis, ...
SUMMIT, N.J., May 2, 2024 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), today announced a real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID), ...
Real-world evidence study shows ANX005 improves muscle strength and functional outcomes in Guillain-Barré Syndrome compared to current treatments. Potential regulatory concerns may arise if the FDA ...